Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.


Sci. Signal., 27 January 2009
Vol. 2, Issue 55, p. ra4
[DOI: 10.1126/scisignal.2000014]


EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma

Qi-Wen Fan1,2,3,4, Christine Cheng1,2,3,4, Zachary A. Knight5,6,7, Daphne Haas-Kogan3,4, David Stokoe3,4, C. David James3,4, Frank McCormick4, Kevan M. Shokat5,6,7, and William A. Weiss1,2,3,4,5*

1 Department of Neurology, University of California, 533 Parnassus Avenue, San Francisco, CA 94143, USA.
2 Department of Pediatrics, University of California, San Francisco, CA 94143, USA.
3 Department of Neurological Surgery and Brain Tumor Research Center, University of California, San Francisco, CA 94143, USA.
4 Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
5 Program in Chemistry and Chemical Biology, University of California, San Francisco, CA 94158, USA.
6 Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158, USA.
7 Howard Hughes Medical Institute, University of California, San Francisco, CA 94158, USA.

Abstract: Amplification of the gene encoding the epidermal growth factor (EGF) receptor (EGFR) occurs commonly in glioblastoma, leading to activation of downstream kinases including phosphatidylinositol 3'-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR). Here, we show that phosphorylation of mTOR and its downstream substrate rpS6 (ribosomal protein S6) are robust biomarkers for the antiproliferative effect of EGFR inhibitors. Inhibition of EGFR signaling correlated with decreased abundance of phosphorylated mTOR (p-mTOR) and rpS6 (p-rpS6) in cells wild type for the gene encoding PTEN (phosphatase and tensin homolog on chromosome 10), a negative regulator of PI3K. In contrast, inhibition of EGFR signaling failed to affect p-mTOR or p-rpS6 in cells mutant for PTEN, which are resistant to EGFR inhibitors. Although the abundance of phosphorylated Akt (p-Akt) decreased in response to inhibition of EGFR signaling, Akt was dispensable for signaling between EGFR and mTOR. We identified an Akt-independent pathway linking EGFR to mTOR that was critically dependent on protein kinase C (PKC). Consistent with these observations, the abundance of EGFR generally correlated with phosphorylation of rpS6 and PKC in primary human glioblastoma tumors, and correlated poorly with phosphorylation of Akt. Inhibition of PKC led to decreased viability of glioma cells regardless of PTEN or EGFR status, suggesting that PKC inhibitors should be tested in glioma. These findings underline the importance of signaling between EGFR and mTOR in glioma, identify PKC{alpha} as essential to this network, and question the necessity of Akt as a critical intermediate coupling EGFR and mTOR in glioma.

* To whom correspondence should be addressed. E-mail: weiss{at}

Citation: Q.-W. Fan, C. Cheng, Z. A. Knight, D. Haas-Kogan, D. Stokoe, C. D. James, F. McCormick, K. M. Shokat, W. A. Weiss, EGFR Signals to mTOR Through PKC and Independently of Akt in Glioma. Sci. Signal. 2, ra4 (2009).

Read the Full Text

Sustained PKC{beta}II activity confers oncogenic properties in a phospholipase D- and mTOR-dependent manner.
M. El Osta, M. Liu, M. Adada, C. E. Senkal, J. Idkowiak-Baldys, L. M. Obeid, C. J. Clarke, and Y. A. Hannun (2014)
FASEB J 28, 495-505
   Abstract »    Full Text »    PDF »
Blockade of Glioma Proliferation Through Allosteric Inhibition of JAK2.
K. He, Q. Qi, C.-B. Chan, G. Xiao, X. Liu, C. Tucker-Burden, L. Wang, H. Mao, X. Lu, F. E. McDonald, et al. (2013)
Science Signaling 6, ra55
   Abstract »    Full Text »    PDF »
Structure-Activity Analysis of Niclosamide Reveals Potential Role for Cytoplasmic pH in Control of Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling.
B. D. Fonseca, G. H. Diering, M. A. Bidinosti, K. Dalal, T. Alain, A. D. Balgi, R. Forestieri, M. Nodwell, C. V. Rajadurai, C. Gunaratnam, et al. (2012)
J. Biol. Chem. 287, 17530-17545
   Abstract »    Full Text »    PDF »
Emerging insights into the molecular and cellular basis of glioblastoma.
G. P. Dunn, M. L. Rinne, J. Wykosky, G. Genovese, S. N. Quayle, I. F. Dunn, P. K. Agarwalla, M. G. Chheda, B. Campos, A. Wang, et al. (2012)
Genes & Dev. 26, 756-784
   Abstract »    Full Text »    PDF »
Acridine Yellow G Blocks Glioblastoma Growth via Dual Inhibition of Epidermal Growth Factor Receptor and Protein Kinase C Kinases.
Q. Qi, K. He, M.-H. Yoo, C.-B. Chan, X. Liu, Z. Zhang, J. J. Olson, G. Xiao, L. Wang, H. Mao, et al. (2012)
J. Biol. Chem. 287, 6113-6127
   Abstract »    Full Text »    PDF »
Protein Kinase C{alpha} Promotes Cell Migration through a PDZ-Dependent Interaction with its Novel Substrate Discs Large Homolog 1 (DLG1).
A. K. O'Neill, L. L. Gallegos, V. Justilien, E. L. Garcia, M. Leitges, A. P. Fields, R. A. Hall, and A. C. Newton (2011)
J. Biol. Chem. 286, 43559-43568
   Abstract »    Full Text »    PDF »
Therapeutic Potential of AZD1480 for the Treatment of Human Glioblastoma.
B. C. McFarland, J.-Y. Ma, C. P. Langford, G. Y. Gillespie, H. Yu, Y. Zheng, S. E. Nozell, D. Huszar, and E. N. Benveniste (2011)
Mol. Cancer Ther. 10, 2384-2393
   Abstract »    Full Text »    PDF »
Pharmacological and Genetic Evaluation of Proposed Roles of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase (MEK), Extracellular Signal-regulated Kinase (ERK), and p90RSK in the Control of mTORC1 Protein Signaling by Phorbol Esters.
B. D. Fonseca, T. Alain, L. K. Finestone, B. P. H. Huang, M. Rolfe, T. Jiang, Z. Yao, G. Hernandez, C. F. Bennett, and C. G. Proud (2011)
J. Biol. Chem. 286, 27111-27122
   Abstract »    Full Text »    PDF »
Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats.
B. Tyler, S. Wadsworth, V. Recinos, V. Mehta, A. Vellimana, K. Li, J. Rosenblatt, H. Do, G. L. Gallia, I.-M. Siu, et al. (2011)
Neuro Oncology 13, 700-709
   Abstract »    Full Text »    PDF »
Nonredundant Functions for Akt Isoforms in Astrocyte Growth and Gliomagenesis in an Orthotopic Transplantation Model.
R. Endersby, X. Zhu, N. Hay, D. W. Ellison, and S. J. Baker (2011)
Cancer Res. 71, 4106-4116
   Abstract »    Full Text »    PDF »
New Strategies in the Molecular Targeting of Glioblastoma: How Do You Hit a Moving Target?.
T. F. Cloughesy and P. S. Mischel (2011)
Clin. Cancer Res. 17, 6-11
   Abstract »    Full Text »    PDF »
Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma.
Q.-W. Fan, C. Cheng, C. Hackett, M. Feldman, B. T. Houseman, T. Nicolaides, D. Haas-Kogan, C. D. James, S. A. Oakes, J. Debnath, et al. (2010)
Science Signaling 3, ra81
   Abstract »    Full Text »    PDF »
Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies.
I. Astsaturov, V. Ratushny, A. Sukhanova, M. B. Einarson, T. Bagnyukova, Y. Zhou, K. Devarajan, J. S. Silverman, N. Tikhmyanova, N. Skobeleva, et al. (2010)
Science Signaling 3, ra67
   Abstract »    Full Text »    PDF »
mTOR signaling in glioblastoma: lessons learned from bench to bedside.
D. Akhavan, T. F. Cloughesy, and P. S. Mischel (2010)
Neuro Oncology 12, 882-889
   Abstract »    Full Text »    PDF »
Airway PI3K Pathway Activation Is an Early and Reversible Event in Lung Cancer Development.
A. M. Gustafson, R. Soldi, C. Anderlind, M. B. Scholand, J. Qian, X. Zhang, K. Cooper, D. Walker, A. McWilliams, G. Liu, et al. (2010)
Science Translational Medicine 2, 26ra25
   Abstract »    Full Text »    PDF »
Science Signaling Podcast: 5 January 2010.
M. B. Yaffe and A. M. VanHook (2010)
Science Signaling 3, pc1
   Abstract »    Full Text »
Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells.
T. W. Miller, J. T. Forbes, C. Shah, S. K. Wyatt, H. C. Manning, M. G. Olivares, V. Sanchez, T. C. Dugger, N. de Matos Granja, A. Narasanna, et al. (2009)
Clin. Cancer Res. 15, 7266-7276
   Abstract »    Full Text »    PDF »
Oncogenic EGFR Signaling Networks in Glioma.
P. H. Huang, A. M. Xu, and F. M. White (2009)
Science Signaling 2, re6
   Abstract »    Full Text »    PDF »
The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis.
D. Guo, I. J. Hildebrandt, R. M. Prins, H. Soto, M. M. Mazzotta, J. Dang, J. Czernin, J. Y.-J. Shyy, A. D. Watson, M. Phelps, et al. (2009)
PNAS 106, 12932-12937
   Abstract »    Full Text »    PDF »
Striking the balance between PTEN and PDK1: it all depends on the cell context.
A. Iwanami, T. F. Cloughesy, and P. S. Mischel (2009)
Genes & Dev. 23, 1699-1704
   Abstract »    Full Text »    PDF »
Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
M. W. Ronellenfitsch, D. P. Brucker, M. C. Burger, S. Wolking, F. Tritschler, J. Rieger, W. Wick, M. Weller, and J. P. Steinbach (2009)
Brain 132, 1509-1522
   Abstract »    Full Text »    PDF »
Alcohol consumption and decreased risk of non-Hodgkin lymphoma: role of mTOR dysfunction.
P. R. Hagner, K. Mazan-Mamczarz, B. Dai, S. Corl, X. F. Zhao, and R. B. Gartenhaus (2009)
Blood 113, 5526-5535
   Abstract »    Full Text »    PDF »
Science Signaling Podcast: 21 April 2009.
M. B. Yaffe and A. M. VanHook (2009)
Science Signaling 2, pc8
   Abstract »    Full Text »
Akt Demoted in Glioblastoma.
P. K. Vogt and J. R. Hart (2009)
Science Signaling 2, pe26
   Abstract »    Full Text »    PDF »
Science Signaling Podcast: 03 February 2009.
P. P. Pandolfi and A. M. VanHook (2009)
Science Signaling 2, pc3
   Abstract »    Full Text »

To Advertise     Find Products

Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882